Naturally Occurring Autoantibodies against Tau Protein Are Reduced in
Parkinson's Disease Dementia by Kronimus, Yannick et al.
RESEARCH ARTICLE
Naturally Occurring Autoantibodies against
Tau Protein Are Reduced in Parkinson’s
Disease Dementia
Yannick Kronimus1, Alexandra Albus1, Monika Balzer-Geldsetzer1, Sarah Straub3,
Elisa Semler3, Markus Otto3, Jens Klotsche4,5, Richard Dodel1,2*, LANDSCAPE
Consortium¶, David Mengel1
1 Department of Neurology, Philipps-University, Marburg, Germany, 2 Department of Neuro-geriatrics,
University Clinic, Essen, Germany, 3 Department of Neurology, University of Ulm, Ulm, Germany,
4 German Rheumatism Research Centre Berlin, a Leibniz Institute, Berlin, Germany, 5 Charite´ University
Medicine Berlin, Institute for Social Medicine, Epidemiology and Health Economics, Berlin, Germany




Altered levels of naturally occurring autoantibodies (nAbs) against disease-associated neu-
ronal proteins have been reported for neurodegenerative diseases, such as Alzheimer’s
(AD) and Parkinson’s disease (PD). Recent histopathologic studies suggest a contribution
of both Lewy body- and AD-related pathology to Parkinson’s disease dementia (PDD).
Therefore, we explored nAbs against alpha-synuclein (αS), tau and β-amyloid (Aβ) in PDD
compared to cognitively normal PD patients.
Materials and Methods
We established three different ELISAs to quantify the nAbs-tau, nAbs-αS, and nAbs-Aβ lev-
els and avidity towards their specific antigen in serum samples of 18 non-demented
(PDND) and 18 demented PD patients (PDD), which were taken from an ongoing multi-cen-
ter cohort study (DEMPARK/LANDSCAPE).
Results
PDD patients had significantly decreased nAbs-tau serum levels compared to PDND
patients (p = 0.007), whereas the serum titers of nAbs-αS and nAbs-Aβ were unchanged.
For all three nAbs, no significant differences in avidity were found between PDD and PDND
cohorts. However, within both patient groups, nAbs-tau showed lowest avidity to their anti-
gen, followed by nAbs-αS, and nAbs-Aβ. Though, due to a high interassay coefficient of
variability and the exclusion of many samples below the limit of detection, conclusions for
nAbs-Aβ are only conditionally possible.
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Conclusion
We detected a significantly decreased nAbs-tau serum level in PDD patients, indicating a
potential linkage between nAbs-tau serum titer and cognitive deficits in PD. Thus, further
investigation in larger samples is justified to confirm our findings.
Introduction
Altered levels of naturally occurring autoantibodies (nAbs) against disease-associatedproteins
have been reported for neurodegenerative diseases, such as Alzheimer's (AD) und Parkinson's
disease (PD) [1–6]. Although the source and function of these autoantibodies is not understood
thus far, evidence has accumulated that nAbs are involved in maintaining physiologic homeo-
stasis. They mostly belong to class G or M immunoglobulins and recognize and induce clear-
ance of altered self-structures, including oxidatively damaged components, dying cells and
aggregated or misfolded proteins [7–10]. Therefore, altered properties or levels of nAbs against
specific proteins may be a disease-causing factor.
Dementia is a frequent and disabling symptom in PD. However, the pathological cause of
Parkinson's disease dementia (PDD) remains unclear [11]. PD is characterized by the loss of
dopaminergic neurons in the substantia nigra along with the presence of Lewy bodies and
Lewy neurites in surviving neurons [12]. A core content of these intraneuronal inclusions is α-
synuclein (αS). In advanced disease stages, Lewy body pathology can also diffusely affect limbic
and neocortical brain regions [13,14]. Clinically, pervasion of Lewy body pathology to these
brain areas has been linked to cognitive deterioration, which can progress to dementia in PD
patients [15]. In addition to cortical Lewy body pathology, AD-type pathology has been
described as a neuropathological substrate of PDD [16]. AD-type pathology includes both
extraneuronal deposition of β-amyloid (Aβ) and intraneuronal accumulation of hyperpho-
sphorylated tau protein.
In animal studies, β-amyloid has been shown to accelerate α-synuclein deposition, suggest-
ing a synergistic interaction between the describedproteins in PD pathology, particularly in
PDD [17].
NAbs recognizing the three describedproteins, including nAbs-αS, nAbs-tau, and nAbs-
Aβ, have been detected in human serum samples. Interestingly, the serum levels of nAbs-αS,
nAbs-tau, and nAbs-Aβ differed significantly between patients and controls in neurodegenera-
tive diseases [1,2,4,5]. These findings prompted us to perform an explorative study to investi-
gate changes in the nAbs levels in PDD compared to PD patients to identify a potential
diagnostic biomarker for PDD.
Materials and Methods
Patients
To implement the explorative study, samples and clinical as well as neuropsychological data of
eighteen non-demented PD (PDND) patients and eighteen PDD patients were taken from the
DEMPARK/LANDSCAPE cohort study [18]. Clinical characterization of our study cohort is
shown in Table 1. Patients were allocated into both groups followingmatching for age (± 5
years) and gender. In addition, we only included patients with disease duration> 5 years, as
disease duration is a major risk factor for dementia in PD. Successful matching is outlined in
Table 1. For enrolment in the DEMPARK/LANDSCAPE study, participants had to meet
Naturally Occurring Autoantibodies and Parkinson‘s Disease Dementia
PLOS ONE | DOI:10.1371/journal.pone.0164953 November 1, 2016 2 / 15
Education and Research (project number
01GI1008C). The FTD study was supported by the
German Federal Ministry of Education and
Research (KNDD - FTLDc), the JPND networks
SOPHIA, BiomarkAPD and Prefrontals, the EU
(FAIR-PARK II), the foundation of the state Baden-
Wu¨rttemberg (D.3830), BIU (Boehringer Ingelheim
University of Ulm Institute (D.5009)). The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: RD is an investigator on
patents on naturally occurring autoantibodies
which are held by the Philipps-University of
Marburg. There are no further patents, products in
development or marketed products with relevance
to the present study to declare. This does not alter
the authors’ adherence to all the PLOS ONE
policies on sharing data and materials.
criteria for the diagnosis ‘idiopathic PD’ according to the UK Parkinson's Disease Society Brain
Bank clinical diagnostic criteria [19]. A diagnosis of PDD was made according to Level II
Movement disorder society task force criteria [20]. The study was conducted in accordance
with the declaration of Helsinki [21]. The study protocol was approved by the Ethics Commit-
tee of the Philipps-University Marburg (No.: 178/07) and subsequently by the Ethics Commit-
tees of the associated centers, which are part of the Dempark/Landscape study. Separate
consent was required for each module. Patients were only included after giving their written
informed consent. In the case that a patient suffered from dementia the legal guardian gave
written informed consent.
As an additional group we included patients with the behavioral variant of frontotemporal
dementia (bvFTD) into our analysis. Patients were diagnosed according to recent Rascovsky
criteria [22]. and were recruited at the department of Neurology in Ulm. Collection and analy-
sis of samples were approved by the Ethics Committees in Ulm (approval number 39/11). All
patients or their next relatives in case of severe dementia gave written informed consent to
their participation in the study. The clinical and demographic characteristics are outlined in
Table 1.
ELISA
NAbs-tau-ELISA. Tau-441 (rPeptide, Bogart, GA, USA) was dissolved in ultrapure water,
stored at -80°C (up to 8 weeks) and treated in an ultrasonic bath for 15 min before coating.
Sixty wells of high-binding 96-well ELISA plates (Immulon Microtiter Plates 2HB “U” Bottom,
Thermo Scientific, Braunschweig, Germany) were coated with 50 μl of 5 μg/ml recombinant
tau-441 peptide in 0.1 M sodium phosphate buffer (2.62 g/l sodium dihydrogen phosphate
monohydrate, 21.71 g/l disodiumhydrogen phosphate heptahydrate in ultrapure water, pH
7.4). The 36 remaining wells were incubated with sodium phosphate buffer only (uncoated
wells). After 24 h at 4°C, the wells were blocked with 180 μl blocking buffer (1x Roti1Block
+ 0.1% Tween-20, Carl Roth, Karlsruhe, Germany) for additional 24 h at 4°C. Serum samples
were diluted 1:50 in blocking buffer (1x Roti1Block + 0.1% Tween-20) and added to coated
Table 1. Patient characteristics.
PDND PDD p-valuea) PD bvFTD p-valueb)
No. of patients 18 18 36 20
Male/female 13/5 13/5 26/10 12/8
Age at taking blood sample [mean ± SD] 71.6 ± 4.1 71.9 ± 4.7 0.851 71.8 ± 4.3 61.7 ± 11.3 0.001
Age range 64–78 61–79 61–79 38–82
Disease duration [mean ± SD]c) 9.6 ± 3.1 11.6 ± 4.8 0.226 10.6 ± 4.1 3.1 ± 2.8 < 0.001
Age at onset of disease [mean ± SD]d) 62.0 ± 5.4 60.3 ± 7.2 0.425 61.1 ± 6.4 58.7 ± 11.2 0.370
H&Y stage, median [min–max] 2.0 [1–4] 3.0 [2–5] < 0.001 Not determined, because H&Y stage was not
examined for FTD
MMSE 28.7 ± 1.1 25.9 ± 2.7 < 0.001 27.3 ± 2.4 24.9 ± 4.5 0.008
Abbreviations: PDND = non-demented Parkinson’s disease patients; PDD = Parkinson’s disease with dementia; PD = patients with Parkinson’s disease
(PDND and PDD patients combined); bvFTD = patients with behavioral variant of frontotemporal dementia; H&Y = Hoehn & Yahr; MMSE = Mini Mental
State Examination. For statistical analysis, the Student’s t-test and Mann-Whitney-U test were applied.
a PDND compared to PDD
b PD (PDND and PDD patients combined) compared to bvFTD
c defined as years since initial diagnosis for PD and years since first symptoms for bvFTD
d defined as age at initial diagnosis for PD and age at first symptoms for bvFTD
doi:10.1371/journal.pone.0164953.t001
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and uncoated wells as double triplets (50 μl/well). A standard curve (including blank) was gen-
erated by sequential dilution of a monoclonal Anti-tau antibody (Anti-tau antibody (ab22261),
Abcam, Cambridge,MA, USA) in blocking buffer. In addition, a pooled serum standard, gen-
erated by mixing a variety of patient samples, was included in every assay. Plates were incu-
bated with samples for 1 h at ambient temperature (AT) and shaken on an orbital platform
shaker (Unimax 1010, Heidolph, Schwabach, Germany) at 100 rpm.
To evaluate the avidity of nAbs-tau, 8 M of urea per serum sample was added to one of the
triplets of both coated and uncoated wells for 60 s as described by Fialova et al. [23]. Simulta-
neously, washing solution was added to the remaining triplets and samples for standard
curve. The quotient of serum samples treated with urea, divided by the serum samples treated
with washing solution, was set as the avidity because the denaturing agent urea breaks down
the antibody-antigen complexes. Correspondingly, avidity reduction was calculated via avid-
ity subtracted from 1. Afterwards, a second blocking step with 180 μl of blocking buffer was
performed, and the sample was shaken with 100 rpm for 1 h at AT. Detection antibodies
were added to the wells for 1 h at AT and were shaken at 100 rpm (50 μl/well; for standard
curve: biotinylated Goat Anti-Mouse IgG Antibody, Vector, Burlingame, CA, USA, 1:20,000
in blocking buffer; for serum samples and standard: Goat Anti-Human IgG, Fc-Biotin, Dia-
nova, Hamburg, Germany, 1:20,000 in blocking buffer). Then, the samples were incubated
with 50 μl/well of streptavidin-peroxidase (Streptavidin-HRP, R&D Systems, Minneapolis,
MN, USA, 1:200 in blocking buffer) and shaken at 100 rpm for 20 min at AT. The assay was
developed using 50 μl/well of 3,3‘,5,5‘-tetramethylbenzidine (TMB, Merck, Darmstadt, Ger-
many). After 20 min, the reaction was stopped by adding 25 μl/well of 5% sulfuric acid (Carl
Roth, Karlsruhe, Germany). The optical density (OD) of the yellow color was measured at
450 nm using a microplate reader (Infinite 200 PROMicroplate Reader, Tecan, Crailsheim,
Germany). All incubation steps were performed in the dark. Up to and including TMB addi-
tion, the wells were washed three times with 300 μl 1x PBS (8 g/l sodium chloride, 0.2 g/l
potassium chloride, 1.44 g/l disodium hydrogen phosphate, and 0.24 g/l potassium dihydro-
gen phosphate) + 0.05% Tween-20 after each step using an Amersham Biotrak II Plate
Washer (GE Healthcare Europe, Freiburg, Germany).
NAbs-αS-ELISA. Only differences compared to the nAbs-tau ELISA are outlined. Recom-
binant αS (Alpha-Synuclein, rPeptide, Bogart, USA) was dissolved in ultrapure water and
stored at -20°C (up to 8 weeks). Coating was performedwith 3 μg/ml αS in PBS (Biochrom
GmbH, Berlin, Germany). Uncoated wells were incubated with PBS. A standard curvewas gen-
erated with nAbs-αS, which were isolated from human intravenous immunoglobulinG (IVIg
Gamunex, Grifols GmbH, Frankfurt, Germany) via affinity chromatography as previously
described [1]. Goat Anti-Human IgG, Fc-Biotin (Dianova GmbH, Hamburg, Germany,
1:20,000 in blocking buffer) was used as the detection antibody.
nAbs-Aβ-ELISA. Only differences compared to the nAbs-tau ELISA are outlined. Recom-
binant Aβ1–42 (Amyloid-Beta 1–42, rPeptide, Bogart, USA) was dissolved in 10% DMSO, sub-
sequently diluted in 90% 0.05 M sodium carbonate buffer (1.59 g/l sodium carbonate, 2.93 g/l
sodium hydrogen carbonate in ultrapure water, pH 9.6), treated in an ultrasonic bath for 10
min and stored at -80°C (up to 4 weeks).Wells were coated with 10 μg/ml Aβ. A standard
curvewas generated with nAbs-Aβ, which were isolated from human intravenous immuno-
globulin G (IVIg Gamunex, Grifols, Frankfurt, Germany) via affinity chromatography [24].
Serum samples were diluted 1:25 in blocking buffer and goat Anti-Human IgG, Fc-Biotin (Dia-
nova GmbH, Hamburg, Germany, 1:20,000 in blocking buffer) was used as the detection
antibody.
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Analysis
First, the mean OD of all triplets was determined. To eliminate background signals, the blank
was subtracted from each standard and serum signals of uncoated wells were subtracted from
the corresponding serum signals of coated wells. With known concentrations and ODs of the
standards, a standard curve for all ELISA plates was generated using the 4 parameter logistic
nonlinear regression model. The quotient of the serum sample treated with urea divided by the
serum sample treated with washing solution was calculated to generate the avidity reduction.
To check the interassay coefficient of variability, all ELISA plates contained a pooled serum
standard. If the nAbs levels were not evaluable due to one of the following criteria, the corre-
sponding values were restricted from further analysis.
1. background signal higher than sample signal
2. sample signal lower than limit of detection, calculated as
LOD = (meanblank + 1.645(SDblank)) + 1.645(SDlowest sample) [25]
3. increasing signal after urea treatment
Therefore, the evaluation of the nAbs-tau-ELISA included 14 PDND (11 with urea) and 15
PDD (12 with urea) samples, the nAbs-αS-ELISA 17 PDND (14 with urea) and 17 PDD (also
17 with urea) patients, respectively. After application of the criteria, 13 PDND (8 with urea)
and 11 PDD (7 with urea) samples were incorporated in the evaluation of the nAbs-Aβ-ELISA.
In an additional analysis, we also measured nAbs titers of bvFTD patients. Here, the evalua-
tion of the nAbs-tau-ELISA included 18, the nAbs-αS- and nAbs-Aβ-ELISA 20 bvFTD
patients, respectively.
Statistical Analysis
For statistical analysis, SPSS (version 22.0.0.0, IBM SPSS Statistics, Chicago, USA) and STATA
12.1 (Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.) was used. Nor-
mal distribution of variables of interest was tested by a Kolmogorov-Smirnov test. Group dif-
ferences between PDND and PDD were tested by generalized linear mixed models to account
for the matched case-control study design. Differences within the patient groups were tested
using the paired-samples t-test or theWilcoxon signed-rank test. ANOVA or Kruskal-Wallis
test with a following post-hocmultiple comparison procedure (Scheffe’s procedure) was used
to compare more than two groups. Student's t-test or the Mann-Whitney-U test was used for
the test of group differences between PD and bvFTD as appropriate. The significance threshold
was set to p< 0.05 (p< 0.01; p< 0.001).
Results
High reproducibility of nAbs-tau-ELISA and nAbs-αS-ELISA
First, we tested the interassay coefficient of variability (CV) of our ELISAs using the serum
standard from each ELISA plate. The optical density (OD) of the pooled serum standard
showed only small differences between all assay plates in nAbs-tau-ELISA (serum standard
OD: 0.51 ± 0.08; Fig 1A2) and nAbs-αS-ELISA (serum standard OD: 1.65 ± 0.11; Fig 1B2). The
interassay CV was calculated as the percentage of the standard deviation (SD) from the mean
value (% CV = SD x 100 / mean). Interassay CV for both the nAbs-tau-ELISA (15.9%; Fig 1A2)
and nAbs-αS-ELISA (6.7%; Fig 1B2) was acceptable. In addition, interassay variance of the
standard curves of the nAbs-tau-ELISA and the nAbs-αS-ELISA was small, as shown by highly
overlapping standard curves (Fig 1A1 and 1B1). In contrast, ODs of the serum standard
Naturally Occurring Autoantibodies and Parkinson‘s Disease Dementia
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showed significant variations in the nAbs-Aβ-ELISA, resulting in an interassay CV of 41.7%.
Conclusions from the nAbs-Aβ-ELISA are therefore only conditionally possible and are pre-
sented in S1 Fig.
We also calculated the intraassay CV as the percentage of SD from the mean for each serum
sample. The intraassay CV was 5.5 ± 1.9% for nAbs-tau, 4.9 ± 1.5% for nAbs-αS, and
7.1 ± 3.5% for nAbs-Aβ ELISA (data not shown).
Reduced nAbs-tau serum level in PDD patients
Serumwas obtained from 18 PDND and 18 PDD patients who were between 61 and 79 years
of age. The demographic characteristics and clinical features of the groups are outlined in
Table 1.
To compare the nAbs serum levels between PDND and PDD patients, the relative ODs
(patient serum sample OD divided by serum standard OD) of serumnAbs are given. The
mean relative OD of nAbs-tau was 1.46 ± 0.93 for PDND and 0.75 ± 0.47 for PDD patients.
Here, significant differences between both groups were detected (Fig 2A and S1 Table). In con-
trast, nAbs-αS (PDND: OD = 0.15 ± 0.10, PDD: OD = 0.28 ± 0.28; Fig 2B and S1 Table)
showed no significant differences between the groups in terms of the mean relative OD.
Fig 1. Interassay variance. Figure shows standard curves (A1, B1) of single ELISA plates (grey) and mean standard
curves (black) of nAbs-tau-ELISA (A1) and nAbs-αS-ELISA (B1). Furthermore, single (grey crosses) and mean ODs of the
pooled serum standard (A2, B2) are displayed for nAbs-tau-ELISA (A2) and nAbs-αS-ELISA (B). Data are shown as the
mean ± SD.
doi:10.1371/journal.pone.0164953.g001
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In both cases, treatment with 8 M urea resulted in a significant reduction of the mean rela-
tive OD (Fig 2A and 2B and S1 Table; nAbs-tau: PDND: OD = 0.22 ± 0.16, PDD:
OD = 0.26 ± 0.18; nAbs-αS: PDND: OD = 0.06 ± 0.05, PDD: OD = 0.10 ± 0.11).
In order to provide a more comprehensive picture on nAbs in neurodegenerative diseases,
we expanded our investigations to another disorder. We measured nAbs titers in serumof
patients suffering from the behavioral variant of fronto-temporal dementia (bvFTD). NAbs-
tau and nAbs-αS showed a relative mean OD of 1.63 ± 1.46 and 0.48 ± 0.19, respectively. Sig-
nificant differences were found for nAbs-αS but not for nAbs-tau when comparing the FTD
with the PD group (including PDND and PDD patients). In conclusion, FTD patients exhib-
ited a higher nAbs-αS serum level than patients with Parkinson’s disease (S2A and S2B Fig and
S2 Table).
Unchanged avidity of investigated nAbs between PDND und PDD
patients
Next, we explored the avidity reduction of the nAbs to their antigen using treatment with 8 M
urea. The decrease in avidity was stronger for nAbs-tau (PDND: OD = 0.82 ± 0.14, PDD:
OD = 0.73 ± 0.13) than for nAbs-αS (PD: OD = 0.44 ± 0.26, PDD: OD = 0.52 ± 0.32) (Fig 3
and S3 Table). We tested for statistically relevant differences in the avidity of the nAbs, whereat
no one was found between the two patient groups (p> 0.05; Fig 3 and S3 Table). However,
within the patient groups, especially within the PDND group, we observeddifferences between
the nAbs, indicating the following order in avidity: nAbs-αS> nAbs-tau (PDND: p< 0.001,
PDD: p = 0.057; Fig 3 and S3 Table).
In addition to the OD dependent evaluation, we also analyzed nAbs levels and avidity based
on the concentration, which was calculated with the aid of the standard curves and normalized
to the PDND group. This second evaluation was run due to a nonexistent proportionality
betweenOD and concentration when using the 4 parameter logistic nonlinear regression
Fig 2. Distribution of relative serum sample ODs of nAbs-tau- (A) and nAbs-αS-ELISA (B). The relative serum sample OD (related to serum
standard OD) of each non-demented (PDND) and demented Parkinson’s disease (PDD) patient was determined without (nAbs) and with urea treatment
(nAbs + urea). For an overview of their distribution, box plots show the median, 25% and 75% quartile. 50% of the generated data are located in the
box and whiskers represent the minimum and maximum value. NAbs-tau OD showed significant differences between PDND and PDD patients (A;
**p = 0.007). Treatment with 8 M urea caused significant reduction of ODs of nAbs-tau (A; PDND: ***p = 0.002; PDD: ***p < 0.001) and nAbs-αS (B;
PDND: *p = 0.001; PDD: **p < 0.001).
doi:10.1371/journal.pone.0164953.g002
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model for curve fitting. The results are shown in the supplements but yielded comparable find-
ings (S1C2, S1D2 and S3 Figs and S3 and S4 Tables).
Discussion
The main finding of the study is a decreased serum level of nAbs-tau in PD patients with
dementia compared to non-demented PD subjects. To the best of our knowledge, no study
investigating nAbs-tau in PDD subjects has previously been reported. In contrast, the level of
nAbs-αS was unchanged between the two study subgroups. Our findings are consistent with
previous results from a study by Maetzler et al., who also did not observe differences in the
serum level of nAbs-αS between PDND and PDD patients [26]. In addition, we identified
nAbs-tau as less avid than the other investigated nAbs.
One reason for a reduction of free serumnAbs-tau in PDD could be the elevated level of the
serum tau protein in PDD patients compared to PDND patients, resulting in increased anti-
gen-antibody binding and, thereby, decreasing the free nAbs-tau levels in serum. Increased tau
and phospho-tau serum concentrations would be consistent with advanced stages of neurode-
generation and tau pathology–indicatedby neurofibrillary tangles–in the brains of PDD com-
pared to PDND patients [11,27–29]. In line with that, increased tau and phospho-tau levels in
CSF and blood plasma have been demonstrated in the course of cognitive deterioration in AD
[30]. Furthermore, CSF tau and phospho-tau can be increased in PDD compared to PDND
patients [31–34]. However, data on tau levels in the blood of PD patients are currently not
available due to the fact that, in general, blood titers of tau protein are very low and below the
detection level of conventional immunoassays. New ultra-sensitive techniques for the
Fig 3. Distribution of the urea-mediated avidity reduction. For each non-demented (PDND) and demented Parkinson’s
disease (PDD) patient, nAbs-tau and nAbs-αS avidity reduction was calculated. Box plots show the median, 25% and 75%
quartile. 50% of the generated data are located in the box and whiskers represent the minimum and maximum value.
Significant differences were found within (PDND: ***p < 0.001; PDD: p = 0.057) but not between (PDND and PDD: p > 0.05)
the patient groups.
doi:10.1371/journal.pone.0164953.g003
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measurement of tau in human blood are currently evaluated by several groups [30]. However,
as soon as these techniques become available, a longitudinal study in PD involving the mea-
surement of both nAbs-tau and tau protein levels will help to elucidate the reasons for changes
in nAbs levels in the disease process.
In addition to a reduction of free nAbs-tau levels due to increased antigen levels in PDD,
another explanation, namely a reverse effect, is possible. Autoantibodies have been proposed to
participate in the physiological maintenance of homeostasis of their antigens [35]. Therefore,
preexisting reduced levels of nAbs-tau could increase the risk of the accumulation of tau in PD
and thus have etiological importance for PDD. In line with that, passive immunization with
anti-tau monoclonal antibodies in mouse models ameliorated memory and functional deficits
and led to a reduction in the tau-induced histopathological findings [36,37]. Therefore, thera-
peutic considerations may be based on our findings.
Previous research on nAbs-tau with respect to PD is limited to only one study. Terryberry
and colleagues were not able to detect nAbs-tau in serum samples of PD patients [38], but their
study suffers from a major drawback as the researchers used bovine instead of human tau pro-
tein for their assays. The immunoreactivity between both protein species shows considerable
differences, which renders the results difficult to interpret [39]. However, two studies investi-
gating nAbs-tau in AD have been reported. Rosenmann et al. detected nAbs-tau in sera of AD
patients as well as healthy subjects, but reported unchanged levels between both groups [5]. In
a study by Bartos et al., serumnAbs-tau did also not differ betweenAD patients and several
control groups (cognitively normal elderly controls, a mixed group of other dementias, and
patients suffering from inflammatory disorders) [40]. In light of these results, our data suggest
a disease-specificrole of nAbs-tau in PD, especially for the development of cognitive impair-
ments during the disease.
In order to investigate autoantibodies in another neurodegenerative disease we also deter-
mined their serum levels in patients suffering from bvFTD. FTD is a histopathologically het-
erogeneous disorder comprising tau, TAR DNA-binding protein-43, and fused in sarcoma
protein pathology [41]. This is the first report on nAbs in bvFTD. We found comparable levels
of nAbs-tau between PD and bvFTD patients. Interestingly, nAbs-αS serum levels were signifi-
cantly increased in bvFTD patients compared to PD patients. This finding is consistent with
previous results of our group that demonstrated reduced nAbs-αS in PD patients compared to
healthy subjects indicating a disease-specificrole of nAbs-αS in synucleinopathies such as PD
[1].
The functional binding capacity of nAbs depends on both the concentration and avidity
towards their respective antigen. In line with that, an etiological importance of an altered anti-
body avidity has been reported for various diseases, e.g. tuberculosis [42] and autoimmune dis-
orders [43]. We tested the avidity of nAbs in serumof PDND and PDD patients, but found no
significant differences between both groups. However, within both patient groups, nAbs-tau
showed lowest avidity to their antigen. In contrast, studies reporting on multiple sclerosis as
well as other neurological diseases discovered anti-tau antibodies in patients and controls in
both human CSF and serumwith distinct higher avidity [23,44]. The relevance of our finding
remains unclear thus far. However, differences in the avidity of the investigated nAbs towards
their neuronal antigen could indicate diversity in the autoantibody pool so as there may exist
different subgroups of nAbs with specific binding characteristics. Our findings warrant further
investigation to better characterize nAbs in terms of their antigen specificity and avidity.
Despite a careful study design, our assays had certain limitations. The nAbs-Aβ-ELISA
showed a high interassay variability. Aggregation of Aβ during the coating process is a possible
explanation for this effect [45]. In contrast to our assay design, many ELISAs that investigate
nAbs-Aβ antibody titers and that have been reported by others were not controlled for typical
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quality criteria like unspecific background, interassay variability, or limit of detection and thus
their assay performance remains unknown.
The avidity of serumnAbs-tau, nAbs-αS, and nAbs-Aβ towards their antigen differed but
was unchanged between the two study subgroups, PDD and PDND patients. However, our
method using urea as a denaturation agent to break down antibody-antigen binding has limita-
tions. A more sophisticated technique, such as surface plasmon resonance analysis, would pro-
vide more useful information in terms of the binding kinetics and strength.
Due to the exploratory character of this study, our result of an altered nAbs-tau serum level
in PDD patients needs to be replicated in a larger study. Furthermore, longitudinal evaluation
of nAbs levels and their correlation with both the specific antigen concentration and repetitive
neuropsychological cognitive assessments at different time points would be of particular
interest.
Supporting Information
S1 Fig. Results of the nAbs-Aβ-ELISA.A+B. Considerable variation in the standard curves
(A; grey: standard curves of single ELISA plates, black: mean standard curve) and a high inter-
assay coefficient of variability (B; 41.7%; grey crosses: serum standard ODs of single ELISA
plates, black: mean serum standard OD) demonstrate a low reproducibility. C: The relative
serum sample OD (related to serum standard OD) of each non-demented (PDND) and
demented Parkinson's disease (PDD) patient was determinedwithout (nAbs) and with urea
treatment (nAbs + urea). Based thereon and with the aid of the standard curves, nAbs-Aβ con-
centrations (normalized to the PDND group) were determined.D:With both evaluationmeth-
ods, the urea mediated avidity reduction was determined. Both evaluation strategies are very
similar and demonstrate no significant differences between PDND and PDD patients. How-
ever, within both patient groups, nAbs-Aβ are most avid, followed by nAbs-αS and nAbs-tau.
Box plots show the median, 25% and 75% quartile. 50% of the generated data are located in the
box and whiskers represent the minimum and maximum value. Correspondingmean values,
standard deviations and p-values are outlined in S1, S3 and S4 Tables.
(TIF)
S2 Fig. Comparison of nAbs serum titers including patients with behavioral variant of
frontotemporal dementia (bvFTD).NAbs-tau- (A), nAbs-αS- (B) and nAbs-Aβ-ELISAs (C)
were analyzed using the relative serum sample ODs (related to serum standard OD) of each
Parkinson’s disease patient (PD, including PDND and PDD patients) as well as bvFTD patient.
For an overviewof the distribution of the serum sample ODs, box plots show the median, 25%
and 75% quartile. 50% of the generated data are located in the box and whiskers represent the
minimum and maximum value. FTD patients showed significantly increased nAbs-αS serum
levels compared to PD patients (B; p< 0.001).
(TIF)
S3 Fig. Evaluation of nAbs-tau- and nAbs-αS-ELISAbased on the normalizedconcentra-
tion.Using standard curves, the nAbs-tau and nAbs-αS serum concentration of each non
demented (PDND) and demented Parkinson's disease (PDD) patient was determined. After
normalization to the PDND group, nAbs-tau (A) and nAbs-αS (B) concentrations as well as
the urea mediated avidity reductions (C) were compared between and within the two patient
groups. Box plots show the median, 25% and 75% quartile. 50% of the generated data are
located in the box and whiskers represent the minimum and maximum value. Corresponding
mean values, standard deviations and p-values are presented in S3 and S4 Tables.
(TIF)
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S1 Table. Mean relative optical densities (ODs) of serum samples.Relative serum sample
ODs of non-demented (PDND) and demented Parkinson's disease patients (PDD) are shown
as the mean ± SD for each ELISA. For avidity determination, the patient serum samples were
untreated (OD) or treated with urea (OD + urea). P-values: a) PDND compared to PDD
b)PDND: nAbs OD compared to nAbs OD + urea and c) PDD: nAbs OD compared to nAbs
OD + urea.
(PDF)
S2 Table. Mean relative optical densities (ODs) of serum samples including patients with
behavioral variant of frontotemporal dementia (bvFTD).Relative serum sample ODs of
each Parkinson’s disease patient (PD, including PDND and PDD patients) as well as bvFTD
patient are shown as the mean ± SD for each ELISA. For statistical analysis, Student's t-test or
the Mann-Whitney-U test was applied.
(PDF)
S3 Table. Avidity reductions.Avidity reductions of the nAbs were calculated for each non-
demented (PDND) and demented Parkinson's disease (PDD) patient as the quotient of the
urea treated sample divided by the untreated sample. Therefore, the optical density (OD) as
well as the concentration based evaluationmethod was used. Data are shown as the
mean ± SD. P-values. a) PDND compared to PDD. b) nAbs-tau compared to nAbs-αS within
patient groups (comparing two groups). c) nAbs-tau compared to nAbs-αS within patient
groups (comparing three groups). d) nAbs-tau compared to nAbs-Aβ within patient groups
(comparing three groups). e) nAbs-αS compared to nAbs-Aβ within patient groups (comparing
three groups).
(PDF)
S4 Table. Normalized concentrations (Conc.) of serum samples.Using standard curves,
nAbs serum concentrations of non-demented (PDND) and demented Parkinson's disease
patients (PDD) were determined.Here, the mean values ± SD of the normalized concentra-
tions (to the median of the PDND group) are shown. For avidity determination, the patient
serum samples were untreated (Conc.) or treated with urea (Conc. + urea). P-values: a) PDND
compared to PDD b) PDND: nAbs concentration compared to nAbs concentration + urea and
c) PDD: nAbs concentration compared to nAbs concentration + urea.
(PDF)
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